1
|
Permuth-Wey J and Sellers TA: Epidemiology
of ovarian cancer. Methods Mol Biol. 472:413–437. 2009. View Article : Google Scholar : PubMed/NCBI
|
2
|
Heintz AP, Odicino F, Maisonneuve P, Quinn
MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S and Beller U:
Carcinoma of the ovary. FIGO 26th annual report on the results of
treatment in gynecological cancer. Int J Gynecol Obstet. 95 Suppl
1:S161–S192. 2006. View Article : Google Scholar
|
3
|
Takano M, Sugiyama T, Yaegashi N, Sakuma
M, Suzuki M, Saga Y, Kuzuya K, Kigawa J, Shimada M, Tsuda H, et al:
Low response rate of second-line chemotherapy for recurrent or
refractory clear cell carcinoma of the ovary: A retrospective Japan
clear cell carcinoma study. Int J Gynecol Cancer. 18:937–942. 2008.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Colombo PE, Mourregot A, Fabbro M,
Gutowski M, Saint-Aubert B, Quenet F, Gourgou S and Rouanet P:
Aggressive surgical strategies in advanced ovarian cancer: A
monocentric study of 203 stage IIIC and IV patients. Eur J Surg
Oncol. 35:135–143. 2009. View Article : Google Scholar : PubMed/NCBI
|
5
|
Takano M, Goto T, Kato M, Sasaki N,
Miyamoto M and Furuya K: Short response duration even in responders
to chemotherapy using conventional cytotoxic agents in recurrent or
refractory clear cell carcinomas of the ovary. Int J Clin Oncol.
18:556–557. 2013. View Article : Google Scholar : PubMed/NCBI
|
6
|
Miyamoto M, Takano M, Goto T, Kato M,
Sasaki N, Tsuda H and Furuya K: Clear cell histology as a poor
prognostic factor for advanced epithelial ovarian cancer: A single
institutional case series through central pathologic review. J
Gynecol Oncol. 24:37–43. 2013. View Article : Google Scholar : PubMed/NCBI
|
7
|
Kim HS, Kim TH, Chung HH and Song YS: Risk
and prognosis of ovarian cancer in women with endometriosis: A
meta-analysis. Br J Cancer. 110:1878–1890. 2014. View Article : Google Scholar : PubMed/NCBI
|
8
|
Pearce CL, Templeman C, Rossing MA, Lee A,
Near AM, Webb PM, Nagle CM, Doherty JA, Cushing-Haugen KL, Wicklund
KG, et al: Association between endometriosis and risk of
histological subtypes of ovarian cancer: A pooled analysis of
case-control studies. Lancet Oncol. 13:385–394. 2012. View Article : Google Scholar : PubMed/NCBI
|
9
|
Kim HS, Kim MA, Lee M, Suh DH, Kim K, No
JH, Chung HH, Kim YB and Song YS: Effect of endometriosis on the
prognosis of ovarian clear cell carcinoma: A two-center cohort
study and meta-analysis. Ann Surg Oncol. 22:2738–2745. 2015.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Kumar S, Munkarah A, Arabi H,
Bandyopadhyay S, Semaan A, Hayek K, Garg G, Morris R and Ali-Fehmi
R: Prognostic analysis of ovarian cancer associated with
endometriosis. Am J Obstet Gynecol. 204(63): e1–e7. 2011.
|
11
|
Orezzoli JP, Russell AH, Oliva E, Del
Carmen MG, Eichhorn J and Fuller AF: Prognostic implication of
endometriosis in clear cell carcinoma of the ovary. Gynecol Oncol.
110:336–344. 2008. View Article : Google Scholar : PubMed/NCBI
|
12
|
Komiyama S, Aoki D, Tominaga E, Susumu N,
Udagawa Y and Nozawa S: Prognosis of Japanese patients with ovarian
clear cell carcinoma associated with pelvic endometriosis:
Clinicopathologic evaluation. Gynecol Oncol. 72:342–346. 1999.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Erzen M, Rakar S, Klancnik B and Syrjänen
K: Endometriosis-associated ovarian carcinoma (EAOC): An entity
distinct from other ovarian carcinomas as suggested by a nested
case-control study. Gynecol Oncol. 83:100–108. 2001. View Article : Google Scholar : PubMed/NCBI
|
14
|
Melin A, Lundholm C, Malki N, Swahn ML,
Sparen P and Bergqvist A: Endometriosis as a prognostic factor for
cancer survival. Int J Cancer. 129:948–955. 2011. View Article : Google Scholar : PubMed/NCBI
|
15
|
Bai H, Cao D, Yuan F, Sha G, Yang J, Chen
J, Wang Y, Zhang Z and Shen K: Prognostic value of endometriosis in
patients with stage I ovarian clear cell carcinoma: Experiences at
three academic institutions. Gynecol Oncol. 143:526–531. 2016.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Ye S, Yang J, You Y, Cao D, Bai H, Lang J,
Chen J and Shen K: Comparative study of ovarian clear cell
carcinoma with and without endometriosis in People's Republic of
China. Fertil Steril. 102:1656–1662. 2014. View Article : Google Scholar : PubMed/NCBI
|
17
|
Kajiyama H, Shibata K, Mizuno M, Yamamoto
E, Fujiwara S, Umezu T, Suzuki S, Nakanishi T, Nagasaka T and
Kikkawa F: Postrecurrent oncologic outcome of patients with ovarian
clear cell carcinoma. Int J Gynecol Cancer. 22:801–806. 2012.
View Article : Google Scholar : PubMed/NCBI
|
18
|
Shimokawa M, Ohki M and Kaku T:
Correlation of progression-free and post-progression survival with
overall survival in phase III trials of first-line chemotherapy for
advanced epithelial ovarian cancer. Eur J Gynaecol Oncol.
36:370–375. 2015.PubMed/NCBI
|
19
|
Anglesio MS, Papadopoulos N, Ayhan A,
Nazeran TM, Noë M, Horlings HM, Lum A, Jones S, Senz J, Seckin T,
Ho J, Wu RC, Lac V, Ogawa H, Tessier-Cloutier B, Alhassan R, Wang
A, Wang Y, Cohen JD, Wong F, Hasanovic A, Orr N, Zhang M, Popoli M,
McMahon W, Wood LD, Mattox A, Allaire C, Segars J, Williams C,
Tomasetti C, Boyd N, Kinzler KW, Gilks CB, Diaz L, Wang TL,
Vogelstein B, Yong PJ, Huntsman DG and Shih IM: Cancer-Associated
Mutations in Endometriosis without Cancer. N Engl J Med.
376:1835–48. 2017. View Article : Google Scholar : PubMed/NCBI
|
20
|
Yamashita Y, Akatsuka S, Shinjo K, Yatabe
Y, Kobayashi H, Seko H, Kajiyama H, Kikkawa F, Takahashi T and
Toyokuni S: Met is the most frequently amplified gene in
endometriosis-associated ovarian clear cell adenocarcinoma and
correlates with worsened prognosis. PLoS One. 8:e577242013.
View Article : Google Scholar : PubMed/NCBI
|
21
|
Itamochi H, Oishi T, Oumi N, Takeuchi S,
Yoshihara K, Mikami M, Yaegashi N, Terao Y, Takehara K, Ushijima K,
Watari H, Aoki D, Kimura T, Nakamura T, Yokoyama Y, Kigawa J and
Sugiyama T: Br J Cancer. 2017.doi: 10.1038/bjc.2017.228 (Epub ahead
of print). View Article : Google Scholar : PubMed/NCBI
|